Combination pirfenidone and inhaled N-acetylcysteine therapy for IPF: Does it take these two to tango?

Respirology

Volumn 20, Issue 3, 2015, Pages 359-360

  Velez, Maria I ^a,b   Nambiar, Anoop M ^a,b  

^a UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^b SOUTH TEXAS VETERANS HEALTH CARE SYSTEM   (United States)

Author keywords

acetylcysteine; combination drug therapy; disease progression; idiopathic pulmonary fibrosis; pirfenidone

Indexed keywords

ACETYLCYSTEINE; PIRFENIDONE; PYRIDONE DERIVATIVE;

CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL RESEARCH; CLINICAL TRIAL (TOPIC); DISEASE SEVERITY; DOWN SYNDROME; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; EDITORIAL; EMPHYSEMA; FIBROSING ALVEOLITIS; FORCED VITAL CAPACITY; HEALTH CARE COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LUNG DIFFUSION CAPACITY; MONOTHERAPY; NEOPLASM; PRIORITY JOURNAL; PROGNOSIS; PULMONARY HYPERTENSION; TREATMENT OUTCOME; FEMALE; IDIOPATHIC PULMONARY FIBROSIS; MALE;

ACETYLCYSTEINE; FEMALE; HUMANS; IDIOPATHIC PULMONARY FIBROSIS; MALE; PYRIDONES;

EID: 84924531115     PISSN: 13237799     EISSN: 14401843     Source Type: Journal    
DOI: 10.1111/resp.12487     Document Type: Editorial

References (10)

1. Raghu G, Collard HR, Egan JJ, Martinez FJ, Behr J, Brown KK, Colby TV, Cordier JF, Flaherty KR, Lasky JA, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidenced based guidelines for diagnosis and management. Am. J. Respir. Crit. Care Med. 2011; 183: 788-824.
2. King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, et al. A Phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2083-2092.
3. Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, et al. Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2071-2082.
4. Martinez FJ, de Andrade JA, Anstrom KJ, King TE Jr, Raghu G, for the Idiopathic Pulmonary Fibrosis Clinical Research Network. Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis. N. Engl. J. Med. 2014; 370: 2093-2101.
5. Wuyts WA, Antoniou KM, Borensztajn K, Costabel U, Cottin V, Crestani B, Grutters JC, Maher TM, Poletti V, Richeldi L, et al. Combination therapy: the future of management for idiopathic pulmonary fibrosis? Lancet Respir. Med. 2014; 2: 933-942.
6. Homma S, Sugino K, Sakamoto S,. The usefulness of a disease severity staging classification system for IPF in Japan: 20 years of experience from empirical evidence to randomized control trial enrollment. Respir. Invest. 2015; 53: 7-12.
7. Sakamoto S, Muramatsu Y, Satoh K, Ishida F, Kikuchi N, Sano G, Sugino K, Isobe K, Takai Y, Homma S,. Effectiveness of combined therapy with pirfenidone and inhaled N-acetylcysteine for advanced idiopathic pulmonary fibrosis: a case-control study. Respirology 2015; 20: 445-452.
8. Ley B, Ryerson CJ, Vittinghoff E, Ryu JH, Tomassetti S, Lee JS, Poletti V, Buccioli M, Elicker BM, Jones KD, et al. A multidimensional index and staging system for idiopathic pulmonary fibrosis. Ann. Intern. Med. 2012; 156: 684-691.
9. Muramatsu Y, Sugino K, Kikuchi N, Sakaguchi S, Sato K, Sano G, Isobe K, Sakamoto S, Takai Y, Tatebe J, et al. Efficacy of inhaled N-acetylcysteine on lung function and redox balance in idiopathic pulmonary fibrosis. Am. J. Respir. Crit. Care Med. 2011; 183: A1529.
10. Homma S, Azuma A, Taniguchi H, Ogura T, Mochiduki Y, Sugiyama Y, Nakata K, Yoshimura K, Takechi M, Kudoh S, for the Japan NAC Clinical Study Group. Efficacy of inhaled N-acetylcysteine monotherapy in patients with early stage idiopathic pulmonary fibrosis. Respirology 2012; 17: 467-477.